Intellia Therapeutics(NTLA) Prnewswire·2025-02-25 10:45Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between July 30, 2024, and January 8, 2025 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for Intellia investors who were impacted by the company's failure to disclose critical information regarding its Phase 1/2 study of NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [2] - Defendants allegedly misled investors by expressing confidence in the study's timeline, stating that the first patient would be dosed in the second half of 2024, while failing to reveal a significant decline in demand for viral-based editing methods [2] - On January 9, 2025, Intellia announced a reorganization, halting all NTLA-3001 research and reducing its workforce by 27%, which led to a significant drop in the company's stock price from 10.20 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request to be appointed as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]